Ovarian Neoplasia (Granulosa Cell Tumor, Adenocarcinoma)

Ovarian neoplasia encompasses a diverse group of primary and metastatic tumors arising from the ovarian parenchyma, stroma, or germ cells. In female dogs and cats, ovarian tumors are relatively uncommon, with an incidence of 0.5% to 1.2% of all canine neoplasms and even lower in felines. The most frequently diagnosed primary ovarian tumors in dogs are granulosa cell tumors (GCTs), accounting for approximately 50% of all ovarian neoplasms, followed by adenocarcinomas (papillary cystadenocarcinomas) and dysgerminomas. In cats, ovarian adenocarcinomas are more prevalent than GCTs. These tumors can be functional, secreting estrogen, progesterone, or androgens, leading to significant endocrine disturbances such as persistent estrus, cystic endometrial hyperplasia, and pyometra. Non-functional tumors may remain clinically silent until they reach a large size or metastasize. Ovarian neoplasia can occur at any age but is most common in middle-aged to older intact females, with a median age of 10 years in dogs and 10-12 years in cats. Early diagnosis and surgical intervention are critical for optimal outcomes, as malignant tumors carry a guarded to poor prognosis, especially with metastasis.

The exact etiology of ovarian neoplasia remains largely unknown, but several factors are implicated. Genetic predisposition plays a significant role, with certain breeds such as Boxers, German Shepherds, and English Bulldogs having a higher incidence of GCTs. Hormonal influences are critical; prolonged exposure to gonadotropins (LH, FSH) due to repeated estrous cycles without pregnancy, or exogenous hormone administration, may promote neoplastic transformation. Estrogen and progesterone receptors are expressed in many ovarian tumors, suggesting a hormone-dependent growth mechanism. In cats, ovarian adenocarcinomas are often associated with feline leukemia virus (FeLV) infection, although the direct oncogenic mechanism is not fully understood. Chronic inflammation, such as that from ovarian cysts or endometriosis, may also contribute. Environmental toxins and carcinogens have been proposed but not definitively proven. Additionally, chromosomal abnormalities and mutations in tumor suppressor genes (e.g., p53) and oncogenes (e.g., K-ras) have been identified in some ovarian tumors, though specific genetic markers are not yet established for routine clinical use.

Ovarian neoplasia is rare in dogs and cats. In dogs, the incidence is estimated at 0.5-1.2% of all tumors, with a mean age of onset around 10 years (range 1-20 years). Certain breeds, including Boxers, German Shepherds, English Bulldogs, and Pointers, appear overrepresented for GCTs. No clear sex predilection exists as it occurs in intact females; spayed females are protected. In cats, ovarian tumors are even rarer, with a reported incidence of 0.7% of all feline tumors. The mean age is 10-12 years, and Siamese and Persian breeds may be at higher risk. Ovarian adenocarcinomas are the most common malignant ovarian tumor in cats, often bilateral and highly metastatic. GCTs are more common in dogs and are often unilateral. The prevalence of functional tumors varies; GCTs are frequently functional, leading to clinical signs of hyperestrogenism or hyperprogesteronism. Adenocarcinomas are often non-functional but can be aggressive, with metastasis to the omentum, liver, and lungs. Overall, ovarian tumors are more common in intact females, and early ovariohysterectomy (OHE) virtually eliminates the risk.

The pathophysiology of ovarian neoplasia involves uncontrolled cellular proliferation of ovarian cell types. Granulosa cell tumors arise from granulosa cells of the ovarian follicles and are often hormonally active. They secrete estrogen, progesterone, or androgens, leading to clinical signs such as persistent estrus, cystic endometrial hyperplasia, and pyometra. The tumor may produce inhibin, which suppresses FSH secretion, but the net effect is often hyperestrogenism. Adenocarcinomas originate from the surface epithelium of the ovary and are typically malignant, with a propensity for local invasion and metastasis via the peritoneal cavity. They may be bilateral and can cause ascites due to peritoneal carcinomatosis. Dysgerminomas, derived from germ cells, are less common and can be malignant. The tumor growth can lead to ovarian enlargement, abdominal distension, and compression of adjacent organs. Hormonal imbalances disrupt the normal estrous cycle, causing irregular cycles, prolonged proestrus/estrus, or anestrus. In intact females, the persistent estrogen stimulation can lead to bone marrow suppression (pancytopenia) and aplastic anemia, a rare but severe complication. Metastasis occurs via lymphatic and hematogenous routes, with common sites being the regional lymph nodes, liver, lungs, and omentum.

Several factors predispose to ovarian neoplasia. Age is a significant risk factor, with most tumors occurring in middle-aged to older intact females. Breed predisposition is evident in dogs, with Boxers, German Shepherds, and English Bulldogs having a higher incidence of GCTs. In cats, Siamese and Persian breeds may be at increased risk. Nulliparity and repeated estrous cycles without pregnancy may increase the risk due to prolonged gonadotropin stimulation. Exogenous hormone administration, such as estrogen or progestins for contraception or estrus suppression, has been implicated in the development of ovarian tumors, particularly in cats. Genetic mutations and inherited susceptibility play a role, though specific genes are not fully characterized. Chronic ovarian inflammation or cysts may predispose to neoplastic transformation. Environmental factors, such as exposure to carcinogens, are speculative. Importantly, early ovariohysterectomy (OHE) before the first estrus significantly reduces the risk of ovarian neoplasia, as well as mammary tumors.

Clinical signs of ovarian neoplasia vary depending on the tumor type, hormonal activity, and presence of metastasis. Many tumors are non-functional and may be incidental findings during routine examination or imaging. Functional tumors, especially GCTs, cause endocrine disturbances. Hyperestrogenism leads to persistent estrus, vulvar swelling, serosanguineous vaginal discharge, attraction of males, and cytological evidence of cornified vaginal epithelial cells. Prolonged estrogen exposure can cause cystic endometrial hyperplasia and pyometra, with signs of polyuria, polydipsia, lethargy, and abdominal distension. Hyperprogesteronism may result in anestrus, alopecia, and mammary gland enlargement. Androgen-secreting tumors can cause clitoromegaly and male-like behavior. Large tumors may cause abdominal distension, palpable abdominal mass, and occasionally pain. Malignant tumors with metastasis may present with weight loss, anorexia, ascites, dyspnea (if pulmonary metastasis), and lameness (if bone metastasis). In cats, ovarian adenocarcinoma often presents with abdominal mass and ascites. Bone marrow suppression from hyperestrogenism can lead to pale mucous membranes, petechiae, and secondary infections.

Differential diagnoses for ovarian neoplasia include: 1) Ovarian cysts (follicular, luteal, epithelial) – these are non-neoplastic fluid-filled structures that can cause similar hormonal signs; ultrasonography shows anechoic structures, and cytology/histopathology is definitive. 2) Pyometra – presents with vaginal discharge, systemic illness, and uterine distension; imaging shows fluid-filled uterus, and ovarian tumors may be concurrent. 3) Cystic endometrial hyperplasia (CEH) – often associated with hormonal imbalance, may coexist with ovarian tumors; histopathology of the uterus is needed. 4) Mammary gland neoplasia – may present with palpable masses, but location and imaging differentiate. 5) Other abdominal masses (e.g., splenic, hepatic, renal) – imaging and biopsy are necessary. 6) Ectopic pregnancy – rare, but can cause abdominal mass and hormonal signs. 7) Foreign body granuloma – history of ingestion or migration. 8) Peritonitis – may cause abdominal effusion and pain. 9) Uterine leiomyoma – benign smooth muscle tumor, can be differentiated by histopathology. 10) Vaginal neoplasia – may cause discharge and mass, but vaginal examination and imaging localize the lesion. Definitive diagnosis requires histopathology of the ovarian tissue.

The diagnostic approach for suspected ovarian neoplasia involves a stepwise algorithm: 1) Signalment and history – note age, breed, intact status, and reproductive history. 2) Complete physical examination – assess for abdominal mass, vulvar swelling, vaginal discharge, and signs of systemic illness. 3) Vaginal cytology – if the female is in estrus or has persistent estrus, cytology may show cornified cells; however, this is not specific. 4) Serum hormone assays – measure estradiol, progesterone, testosterone, and inhibin. Elevated estradiol or inhibin may indicate a functional GCT. 5) Abdominal ultrasonography – the primary imaging modality; it can identify ovarian masses, characterize their echogenicity, and detect uterine changes (CEH, pyometra) and metastasis. 6) Abdominal radiography – may show a soft tissue mass or mineralization in rare cases; useful for detecting metastasis to lungs or liver. 7) Fine-needle aspiration (FNA) of the ovarian mass – can be performed under ultrasound guidance for cytology, but may be inconclusive. 8) Exploratory laparotomy – often necessary for definitive diagnosis and treatment; allows visual inspection, biopsy, and ovariohysterectomy. 9) Histopathology – the gold standard for tumor classification and grading. 10) Staging – if malignancy is confirmed, thoracic radiographs and abdominal ultrasound are recommended to detect metastasis.

Laboratory findings in ovarian neoplasia are variable. Complete blood count (CBC) may reveal anemia, leukocytosis, or thrombocytopenia, especially if hyperestrogenism causes bone marrow suppression. Serum biochemistry may show elevated liver enzymes (ALP, ALT) if metastasis to the liver, or azotemia if renal involvement. Hypercalcemia can occur in some malignant tumors due to paraneoplastic syndromes. Hormonal assays are crucial: elevated estradiol (>20 pg/mL) or progesterone (>2 ng/mL) in a non-pregnant, non-luteal female suggests a functional tumor. Inhibin levels are often elevated in GCTs and can be a useful tumor marker. Testosterone may be elevated in androgen-secreting tumors. Vaginal cytology may show cornified epithelial cells if estrogen is elevated, or parabasal cells if progesterone dominates. Urinalysis may reveal hematuria or proteinuria if there is urinary tract involvement. Cytology of peritoneal fluid, if ascites is present, may show neoplastic cells. Histopathology of the tumor is definitive, with GCTs showing characteristic Call-Exner bodies and adenocarcinomas showing papillary or tubular patterns.

Imaging plays a pivotal role in the diagnosis and staging of ovarian neoplasia. Abdominal ultrasonography is the most sensitive modality. Findings may include: an enlarged ovary with a complex mass, often with cystic areas (GCTs may have a 'honeycomb' appearance); a solid or mixed echogenic mass (adenocarcinoma); uterine changes such as cystic endometrial hyperplasia (multiple anechoic cysts) or pyometra (fluid-filled distended uterus); and evidence of metastasis, such as peritoneal effusion, omental masses, or hepatic nodules. Color Doppler may show increased vascularity. Abdominal radiography can reveal a soft tissue mass in the mid-abdomen, but is less specific. Thoracic radiographs are essential for staging, as pulmonary metastasis appears as nodular interstitial patterns. Computed tomography (CT) provides more detailed cross-sectional imaging and is superior for detecting small metastases and assessing vascular invasion. Magnetic resonance imaging (MRI) is rarely used but can characterize soft tissue extension. Vaginoscopy is not directly useful for ovarian tumors but may help rule out vaginal pathology. Ultrasonographic-guided FNA can be performed for cytology, but histopathology is required for definitive diagnosis.

Cytology and histopathology are essential for definitive diagnosis. Fine-needle aspiration of an ovarian mass may yield cells that are suggestive of neoplasia, but cytology is often inconclusive due to the heterogeneous nature of these tumors. In GCTs, cytology may show clusters of polyhedral cells with abundant cytoplasm and round nuclei, sometimes with Call-Exner bodies (small fluid-filled spaces). Adenocarcinomas may show papillary clusters of epithelial cells with nuclear atypia. Histopathology is the gold standard. GCTs are characterized by a proliferation of granulosa cells arranged in follicular, trabecular, or diffuse patterns, with Call-Exner bodies being a hallmark. The cells may be luteinized, showing abundant eosinophilic cytoplasm. Adenocarcinomas show papillary or tubular growth patterns, with nuclear pleomorphism, mitotic figures, and invasion of the ovarian stroma or capsule. Immunohistochemistry can be helpful: GCTs are positive for inhibin, calretinin, and vimentin, while adenocarcinomas are positive for cytokeratin and epithelial membrane antigen. Dysgerminomas are positive for c-kit and placental alkaline phosphatase. Histopathology also determines the tumor grade and the presence of vascular invasion, which are important prognostic indicators.

The primary treatment for ovarian neoplasia is surgical removal, typically via ovariohysterectomy (OHE). This is both diagnostic and therapeutic, as it removes the tumor and prevents further hormonal stimulation. For functional tumors, OHE resolves the endocrine signs. In cases of extensive metastasis, debulking surgery may be attempted, but the prognosis is poor. Chemotherapy may be considered for malignant tumors, especially adenocarcinomas, with protocols using carboplatin or cisplatin, though data are limited. Hormonal therapy is not effective. Supportive care includes fluid therapy, antibiotics for secondary infections, and blood transfusions if anemia is severe. If hyperestrogenism has caused bone marrow suppression, recovery may take weeks to months after tumor removal. In valuable breeding animals, unilateral ovariectomy may be considered for benign tumors, but this is controversial due to the risk of bilateral disease and the need for staging. However, OHE is the standard of care. Postoperative monitoring includes serial hormone assays to ensure normalization. For cats, FeLV testing is recommended, and if positive, the prognosis is guarded.

The prognosis for ovarian neoplasia depends on the tumor type, stage, and completeness of surgical excision. Benign tumors, such as GCTs without malignant features, have an excellent prognosis after OHE, with resolution of clinical signs and a normal lifespan. Malignant tumors, especially adenocarcinomas, carry a guarded to poor prognosis, particularly if metastasis is present at the time of surgery. The median survival time for dogs with ovarian adenocarcinoma is reported to be around 6-12 months, even with surgery and chemotherapy. Factors indicating a worse prognosis include: bilateral ovarian involvement, tumor rupture, vascular invasion, high mitotic index, and metastasis to lymph nodes or distant organs. Functional tumors that cause bone marrow suppression have a higher risk of complications, but if the tumor is completely removed, the bone marrow may recover. In cats, ovarian adenocarcinomas are highly malignant, and the prognosis is poor, with most cats succumbing to metastatic disease within months. Early detection and surgical intervention improve the outcome. Regular follow-up with imaging and hormone assays is recommended to detect recurrence or metastasis.

Post-treatment follow-up for ovarian neoplasia is crucial, especially for malignant tumors. After OHE, patients should be re-examined at 2 weeks for surgical site evaluation. For benign tumors, no further monitoring is needed, but for malignant tumors, a staging workup is recommended every 3 months for the first year, then every 6 months thereafter. This includes thoracic radiographs to detect pulmonary metastasis and abdominal ultrasound to assess for local recurrence or peritoneal carcinomatosis. Serum hormone levels (estradiol, progesterone, inhibin) should be measured if the tumor was functional, to ensure they return to baseline. If the patient was anemic due to hyperestrogenism, a CBC should be repeated monthly until resolution. For breeding animals, if a unilateral ovariectomy was performed, the remaining ovary should be monitored via ultrasound for compensatory hypertrophy or tumor development. Owners should be educated on the signs of recurrence, such as weight loss, lethargy, or abdominal distension. In cases of metastasis, palliative care may be needed, including pain management and chemotherapy.

Clinical pearls: 1) Always consider ovarian neoplasia in any intact female with persistent estrus, vaginal discharge, or abdominal mass. 2) Ultrasonography is the most valuable diagnostic tool; look for a 'honeycomb' appearance in GCTs. 3) Serum inhibin is a sensitive marker for GCTs; elevated levels are highly suggestive. 4) OHE is curative for benign tumors and resolves hormonal signs. 5) In cats, ovarian adenocarcinoma is often bilateral and metastatic at diagnosis; stage aggressively. Pitfalls: 1) Do not assume a vaginal discharge is due to pyometra without imaging; ovarian tumors can cause similar signs. 2) Avoid fine-needle aspiration of a suspected ovarian mass if the tumor is cystic, as it may rupture and spread malignant cells. 3) Do not delay surgery in a patient with hyperestrogenism, as bone marrow suppression can be fatal. 4) Be cautious with hormone assays; a single progesterone measurement may be misleading if the tumor secretes both estrogen and progesterone. 5) Do not forget to spay the patient; leaving the contralateral ovary in place risks future neoplasia.

There are no specific medical protocols for treating ovarian neoplasia; surgery is the mainstay. However, supportive care may include: 1) Antibiotics: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or cefazolin (22 mg/kg IV q8h) for secondary infections. 2) Fluid therapy: Lactated Ringer's solution at maintenance (60-100 ml/kg/day IV) for dehydration. 3) Blood transfusion: If severe anemia (PCV <20%), administer fresh whole blood or packed red blood cells (10-20 ml/kg IV). 4) Chemotherapy for malignant tumors: Carboplatin (300 mg/m² IV every 3 weeks) or cisplatin (70 mg/m² IV every 3 weeks, with saline diuresis) for dogs; for cats, carboplatin (200 mg/m² IV every 3 weeks) is used, but cisplatin is contraindicated. 5) Hormonal therapy is not effective. 6) For hyperestrogenism-induced bone marrow suppression, use recombinant human erythropoietin (100 IU/kg SC three times weekly) and granulocyte colony-stimulating factor (5 μg/kg SC daily) until recovery. 7) Analgesics: Carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) for postoperative pain. Always consult Plumb's Veterinary Drug Handbook for current dosages and contraindications.

The literature on ovarian neoplasia in dogs and cats is limited to retrospective studies and case series. A landmark study by Patnaik et al. (1976) described the histopathological classification of ovarian tumors in dogs, establishing the criteria for GCTs, adenocarcinomas, and dysgerminomas. Another study by Greenlee and Patnaik (1985) reported that GCTs are the most common ovarian tumor in dogs, with a low metastatic rate, while adenocarcinomas have a high metastatic potential. In cats, a study by Miller et al. (2003) found that ovarian adenocarcinomas are the most common, often bilateral, and carry a poor prognosis. The role of inhibin as a tumor marker was highlighted by a study by Pimentel et al. (2005), which showed elevated serum inhibin levels in dogs with GCTs. Surgical treatment with OHE is universally recommended, and the prognosis is excellent for benign tumors. Chemotherapy protocols are based on extrapolation from other solid tumors, with carboplatin showing some efficacy in case reports. The American College of Theriogenologists (ACT) and European Society for Small Animal Reproduction (EVSSAR) provide guidelines for the management of reproductive tumors, emphasizing early spaying to prevent ovarian neoplasia. Overall, the evidence base is weak, and more prospective studies are needed to establish optimal chemotherapy protocols and prognostic factors.